MPM C Pike

M C Pike

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M C Pike has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 15 October 1998
      • Vol. 58  (20) , 4497-504

    Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility.

    by R K Ross, M C Pike, G A Coetzee, J K Reichardt, M C Yu, H Feigelson, F Z Stanczyk, L N Kolonel, B E Henderson

    The prostate is an androgen-regulated organ, which has led to long-standing interest in the role of androgens in prostate carcinogenesis. Although evidence of a hormonal etiology for prostate cancer is strong, it is almost entirely circumstantial. Much of the problem in proving a causal relationship relates to the continued difficulties in reliably measuring human tissue-specific exposure to endogenous steroid hormones. The international and racial-ethnic variations in prostate cancer incidence, combined with the effects of migration on risk patterns, have suggested that whereas environmental factors are likely to be important, genetic factors might also play a central role in determining prostate cancer risk. We are developing a polygenic model of prostate carcinogenesis focused around a series of genes involved in androgen biosynthesis and androgen activation, transport, and metabolism in the prostate. In this developing model, we have initially targeted four genes based on three main criteria: (a) all encode products that play important roles in inducing androgen stimulation in the prostate; (b) all are polymorphic; and (c) all show substantial allelic variation in the polymorphic marker among the racial-ethnic groups of greatest interest in terms of prostate cancer risk. In addition to studying how the polymorphic markers of interest are related to prostate cancer development within and between racial-ethnic groups, we are concurrently evaluating whether genotypic variations correlate in the anticipated direction with biochemical parameters in vitro and in vivo. We summarize the development of this model and the state of knowledge related to each of the genes comprising the current model. We discuss the extent to which the current model can explain demographic variation in prostate cancer risk as well as the potential for future expansion of the model to incorporate environmental risk factors as well as additional genes. The model, when fully developed, can potentially provide a basis for targeting populations for screening interventions and/or preventive strategies aimed at the multigene products or at the genes themselves.


    • 15 March 1997
      • Vol. 57  (6) , 1020-2

    A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.

    by N Makridakis, R K Ross, M C Pike, L Chang, F Z Stanczyk, L N Kolonel, C Y Shi, M C Yu, B E Henderson, Juergen Reichardt

    Prostate cancer is the most common serious cancer diagnosed in men in the United States. This disease is also characterized by a striking racial/ethnic variation in incidence: highest in African-Americans, intermediate in Caucasians, slightly lower in Latinos, and lowest in Asians. Ample biochemical and epidemiological evidence suggests a role for androgens, particularly testosterone and dihydrotestosterone, in prostate cancer etiology. We have analyzed a candidate gene for prostate cancer, SRD5A2, encoding prostatic steroid 5alpha-reductase type II, which converts testosterone into the more bioactive dihydrotestosterone, for mutations. We report here one amino acid substitution, V89L, which replaces valine at codon 89 with leucine. This substitution is a "germline" (constitutional) DNA polymorphism, and it is common, panethnic, and reduces in vivo steroid 5alpha-reductase activity. This substitution is particularly common among Asians and may explain the low risk for prostate cancer in this population.


    • 15 September 1995
      • Vol. 55  (18) , 3973-5

    Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.

    by J K Reichardt, N Makridakis, B E Henderson, M C Yu, M C Pike, R K Ross

    Elevated dihydrotestosterone levels have been suggested to increase the risk of prostate cancer. The human SRD5A2 gene encodes the type II steroid 5 alpha-reductase, which converts testosterone to the more bioactive compound dihydrotestosterone. We have determined the distribution of a dinucleotide repeat in low-risk Asian-Americans, high-risk African-Americans, and intermediate-risk non-Hispanic Whites. We found this marker to be more polymorphic than previously reported, with some alleles being specific to African-Americans. Genetic variants of the SRD5A2 gene may play a role in predisposition to prostate cancer and in explaining the substantial racial/ethnic variability in risk.


    • 1 July 1991
      • Vol. 51  (13) , 3617-20

    From gene to carcinogen: a rapidly evolving field in molecular epidemiology.

    by P A Jones, J D Buckley, B E Henderson, R K Ross, M C Pike

    Chemical and physical carcinogens leave footprints of their activities on DNA because of the patterns of base changes they induce. Additionally, the conversion of 5-methylcytosine to thymine in CpG sequences leads to a characteristic mutation which can be used to estimate the contribution of endogenous processes to human mutations. Knowledge of the pattern mutations found in genes commonly mutated in human cancer, such as the p53 tumor suppressor gene, allows for predictions to be made on the likelihood of an exogenous DNA-damaging agent being involved. Working from gene to carcinogen is likely to have a profound impact on our understanding of the origins of human cancer.


    • 1 May 1988
      • Vol. 49, 9S-15S

    Re-evaluating the role of progestogen therapy after the menopause.

    by B E Henderson, R K Ross, R A Lobo, M C Pike, T M Mack

    An estrogen-progestogen regimen of hormone replacement therapy has become widely used in recent years, primarily as a means to protect the endometrium from the carcinogenic effects of unopposed estrogen therapy (ERT). In this article, we evaluate the probable effects of this regimen on mortality from endometrial cancer as well as mortality from other chronic diseases. We conclude from this analysis that ERT is to be preferred to combination therapy for postmenopausal women without a uterus, primarily because it is predicted that ERT confers a significantly greater benefit on heart disease risk. In women with a uterus, if progestogens are to be prescribed, they should be given in the lowest possible dose needed to achieve the desired histologic changes in the endometrium, since the predicted loss in heart disease benefit from adding the progestogen is substantial.


    • 1 October 1984
      • Vol. 40  (4)

    Breast cancer.

    by M C Pike, R K Ross


    • 1 August 1982
      • Vol. 42  (8) , 3232-9

    Endogenous hormones as a major factor in human cancer.

    by B E Henderson, R K Ross, M C Pike, J T Casagrande

    Hormone-related cancers account for almost 30% of all cancer cases in the United States. Data from animal experiments and from epidemiological and endocrinological studies in humans support the hypothesis that the individual hormones which control normal growth of target organs can also create the proper conditions for neoplastic transformation. The concept that hormones can cause, i.e., increase the incidence of, human cancer is most developed for the four hormone-related cancers which are numerically the most important, namely, breast, prostate, endometrium, and ovary. Even for these sites, large gaps remain in our knowledge of the responsible hormones and the conditions which create the optimal opportunity for carcinogenesis. Although scanty, the available epidemiological evidence also suggests a hormonal role in the pathogenesis of testis cancer, thyroid cancer, and osteosarcoma. We believe that the primary prevention of all these cancers will probably depend on modification of the factors which affect the secretion and metabolism of the responsible hormones rather than on control of exposure to classical exogenous initiators.